Pharmaceuticals, Biotechnology and Life Sciences
Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.
Inaffit is voluntarily recalling all lots of Natureal light green and dark green capsules to the consumer level after FDA laboratory testing found Natureal to contain sibutramine.
Zenobia Company LLC. of Yonkers, NY is recalling Ground Flax Seed Meal, because they have the potential to be contaminated with Salmonella.
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…
Sanofi and Regeneron Inc. have announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against…
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…
Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…
AstraZeneca has entered into a definitive agreement to acquire Nasdaq-listed ZS Pharma, a biopharmaceutical company based in San Mateo, California.
FDA has approved Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.